Crossject Société Anonyme (EPA:ALCJ)
France
· Delayed Price · Currency is EUR 1.950
+0.010 (0.52%)
Apr 28, 2026, 5:35 PM CET
Crossject Société Anonyme Revenue
In the year 2025, Crossject Société Anonyme had annual revenue of 2.57M EUR, down -37.64%. Crossject Société Anonyme had revenue of 1.03M in the half year ending December 31, 2025, with 32.56% growth.
Revenue
2.57M
Revenue Growth
-37.64%
P/S Ratio
40.08
Revenue / Employee
24.91K
Employees
103
Market Cap
102.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.57M | -1.55M | -37.64% |
| Dec 31, 2024 | 4.12M | 243.00K | 6.28% |
| Dec 31, 2023 | 3.87M | -3.19M | -45.18% |
| Dec 31, 2022 | 7.06M | 583.00K | 9.00% |
| Dec 31, 2021 | 6.48M | 1.64M | 33.77% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sanofi | 47.35B |
| EssilorLuxottica Société anonyme | 28.49B |
| Sartorius Stedim Biotech | 2.98B |
| Ipsen | 3.93B |
| ABIONYX Pharma | 4.10M |
| Euroapi | 852.60M |
| MaaT Pharma | 4.52M |
| Innate Pharma | 9.01M |